Business Wire

MA-BLUECONIC

2.1.2020 15:02:07 CET | Business Wire | Press release

Share
BlueConic Raises $13 Million Series B to Further Expand Its Global Footprint As the Preeminent Customer Data Platform of the Consumer Privacy Era

BlueConic, the world’s leading pure-play customer data platform (CDP), today announced it has closed a $13M Series B funding round led by new investor Spring Lake Equity Partners with contributions from existing investor Sigma Prime Ventures, as well as angel investors. Growing from an estimated $1B in 2019, spending on CDPs is projected to be in the multi-billion dollars in the next 3 years according to several analyst firms, including the CDP Institute and International Data Corp.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005101/en/

Brands that make the customer the center of their marketing and data infrastructure set themselves apart by creating bespoke experiences that offer value in every stage of the customer lifecycle. However, while most brands are still beholden to legacy technologies, agencies, and processes that lack the data speed, accessibility, and privacy controls required to deliver those experiences, BlueConic customers have adopted the CDP to liberate their data and transform their businesses for the future.

“In an era of consumer privacy regulations like GDPR and CCPA, brands are unprepared to orchestrate individualized marketing for every stage of the customer lifecycle while also respecting individual privacy,” says BlueConic CEO and co-founder, Bart Heilbron. “Most brands still lack a single source of customer data truth down to the individual level that is accessible in real time to marketers and their activation channels. That’s why we’ve designed our CDP from inception to meet the ever-evolving needs of the marketer, and we’ll continue to build on that foundation of flexibility as we lead the category into its next stage of maturity.”

“BlueConic stands apart from other customer data platforms in its ability to intelligently store, segment, and activate first-party data across every possible touchpoint without sacrificing speed, flexibility, or privacy compliance,” says Dan MacKeigan, founding partner of Spring Lake Equity Partners and new BlueConic board member with a proven track record of investments in the marketing technology space. “The company has a long history of solving this fundamental challenge in a way that other technologies were never designed, and therefore never able, to do.”

Since BlueConic closed its Series A to establish its go-to-market and headquarters in the United States, revenue has grown 3,000%. The company’s annual contract value quadrupled in the last 3 years, and annual-recurring-revenue grew by 2x last year. In 2019, BlueConic enhanced its end-to-end consent management capabilities to support worldwide consumer privacy regulations, and released AI Workbench, which amplifies predictive modeling capabilities in the platform for both marketing and data science users.

This investment brings BlueConic’s total funding to $25M to date. Both lean and innovative, BlueConic is recognized within the industry as a premier CDP with more than 300 customers globally. BlueConic scored highest overall among 8 CDPs evaluated in The Relevancy Group’s The Relevancy Ring - CDP Buyer’s Guide vendor scorecard in 2019.

About BlueConic

BlueConic, the world’s leading customer data platform, liberates marketers’ first-party data from all the disparate systems in which it exists, and makes it accessible wherever and whenever it is required from marketing. More than 300 consumer and B2B brands, including Hearst Newspapers, Moen, T-Mobile, ING, America’s Test Kitchen, and Franklin Sports, leverage BlueConic to unify their first-party customer data into persistent, person-level profiles, and then activate it across their marketing ecosystem. Founded in 2010, the company is headquartered in Boston, with offices in Europe. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.

About Spring Lake Equity Partners

Spring Lake Equity Partners is a Boston-based growth equity firm. The firm invests equity capital primarily in later-stage, technology-oriented private companies in software, digital media, mobile, data center infrastructure, healthcare IT, and business/financial services. Spring Lake seeks to partner with great management teams to take their businesses to the next level, creating value for all stakeholders. https://springlakeequitypartners.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 14:00:00 CET | Press release

The AI-native collaboration platform reaches 320,000 users across 100+ countries, validates product-led growth and monetization, and prepares to expand its global AI agent ecosystem. Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000

Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release

One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release

Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment

Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release

Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh

BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye